<DOC>
	<DOCNO>NCT02373865</DOCNO>
	<brief_summary>This exploratory double blind randomize active control study design assess effect treatment therapeutical dosage sitagliptin versus therapeutical dosage glimepiride add therapy patient diabetes mellitus type 2 ( T2DM ) patient inadequately control metformin monotherapy .</brief_summary>
	<brief_title>Risk Nocturnal Hypoglycemia Arrhythmias With Sitagliptin Versus Glimepiride Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 Diabetes associate increase cardiovascular morbidity mortality . Among patient insufficiently control metformin multimorbidity polypharmacy common make patient frail cardiovascular complication related hypoglycemic event . This exploratory double blind randomize active control study design assess effect treatment therapeutical dosage sitagliptin versus therapeutical dosage glimepiride add therapy patient T2DM patient inadequately control metformin monotherapy . Examinations perform 5 day record subcutaneous glucose concentration ( CGMS ) holder ECG ( AMEDTEC ) baseline 12 week treatment sitagliptin glimepiride active comparators use combination metformin . With record nocturnal hypoglycemia arrhythmia aim evaluate favorable glycemic profile treatment sitagliptin compare glimepiride . The primary objective risk serious HE drug . The glycemic profile sitagliptin add-on therapy metformin seem favorable compare sulfonylurea glimepiride . Treatment sitagliptin add-on metformin therapy cause less glycemic fluctuation may associate low oxidative stress regulation low grade inflammation . This hypothesis test explorative double blind study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>type 2 diabetes age 4080 year stable dose ≥ 1500 mg metformin maximal tolerate dose metformin &gt; 6 week HbA1c ≥ 7 % ≤ 9.0 % age &lt; 65 year ≥ 7.5 % ≤ 9.0 % age ≥ 65 year able trained perform SMBG inform consent form must sign study specific test procedures do ability understand follow studyrelated instruction Type 1 diabetes previous treatment insulin , GLP1 analogues SU &lt; 6 month HbA1c &gt; 9 % FPG &gt; 15 mmol/l randomization renal impairment eGFR &lt; 60 ml/min medical history severe hypoglycemia define necessity medical assistance &lt; 1 year major cardiovascular event ( MACE ) medical history &lt; 6 month preexist atrial fibrillation , , AV block ≥II degree , pacemaker , implant defibrillator major cardiovascular event medical history &lt; 6 month heart failure NYHA ≥ III contraindication glimepiride sitagliptin excipients accord product information severe cognitive deficit Patients disable read understand informative aspect trial Subject currently enrol yet complete least 30 day since end investigational device drug study ( ) Inability comply study procedure Pregnant breastfeed woman woman without adequate method contraception</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes mellitus type 2</keyword>
	<keyword>nocturnal hypoglycemia</keyword>
	<keyword>metformin monotherapy</keyword>
</DOC>